Welcome to our dedicated page for Cardlytics news (Ticker: $CDLX), a resource for investors and traders seeking the latest updates and insights on Cardlytics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cardlytics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cardlytics's position in the market.
Cardlytics, Inc. announced their first quarter 2024 financial results, showcasing a 5% increase in revenue, 10% growth in billings, and a 20% rise in adjusted contribution year-over-year. Despite a net loss, the company saw positive adjusted EBITDA and improvement in balance sheet, with strong momentum in international business.
Cardlytics, Inc. announced the grant of 38,500 restricted stock units to five new employees as inducements for employment. The grants were made under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units have different vesting schedules, with some vesting in full after one year and others vesting partially over a period of 12 months.